Could a bile acid pill in breast milk protect babies from liver problems?
NCT ID NCT07517276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a bile acid pill (TUDCA) to breastfeeding mothers with fatty liver disease can make their breast milk healthier for their babies. Eighty mother-infant pairs will be randomly assigned to receive TUDCA or a placebo for a short time after birth. The goal is to see if the treatment is safe and improves infant metabolism and development.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tauroursodeoxycholic acid (TUDCA)
What this could lead to
If successful, this could point toward a safe way for mothers with MASLD to improve their breast milk composition and support healthier infant development.
What could go wrong
This is an early Phase 2 trial with only 80 participants, so results may not apply widely. The treatment is for mothers, not directly for infants, and safety or effectiveness may not be confirmed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••